GSK plc announced that the European Medicines Agency, or EMA, validated the marketing authorization application for momelotinib, a potential new oral treatment for myelofibrosis. Momelotinib has a differentiated mechanism of action, with inhibitory ability along three key signaling pathways: Janus kinase 1, and JAK2 and activin A receptor type I, which could address the significant medical needs of myelofibrosis patients with anaemia. The MAA is based on results from key phase III trials, including the pivotal MOMENTUM trial, which met all primary and key secondary endpoints, the company stated.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on GSK:
- GSK’s phase 3 trial of Jemperli meets primary endpoint
- GSK price target lowered to 1,535 GBp from 1,650 GBp at Morgan Stanley
- Jim Simons’ Hedge Fund Renaissance Technologies is Buying These Stocks Now
- Biogen price target raised to $315 from $300 at Oppenheimer
- GSK says GSK3036656 demonstrated early bactericidal activity in Phase IIa study